| P50 | author | Serap Gur | Q89150503 |
| | Wayne J G Hellstrom | Q89786974 |
| P2093 | author name string | Ma Limin | |
| P2860 | cites work | Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix | Q28378851 |
| | Testosterone deficiency and Peyronie's disease: pilot data suggesting a significant relationship | Q33453878 |
| | Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study | Q34403964 |
| | A critical analysis of nonsurgical treatment of Peyronie's disease | Q34525595 |
| | Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease | Q34534562 |
| | Medical management of Peyronie's disease | Q34869735 |
| | Injectable collagenase clostridium histolyticum for Dupuytren's contracture | Q35000980 |
| | Pathophysiology of Peyronie's disease | Q35010236 |
| | Peyronie's disease: a review | Q35082687 |
| | Surgical alternatives for treating Peyronie's disease | Q35914222 |
| | Ultrasound in patients affected with Peyronie's disease | Q36020774 |
| | Peyronie's disease: etiology, epidemiology and medical treatment | Q36314058 |
| | Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie's disease | Q36395176 |
| | Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease | Q36648279 |
| | Pharmacological Management of Peyronie's Disease | Q36757584 |
| | Graft materials in Peyronie's disease surgery: a comprehensive review | Q36785932 |
| | Peyronie's disease (CME). | Q36986101 |
| | A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. | Q53193957 |
| | Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. | Q53230701 |
| | Use of small intestinal submucosa graft for the surgical management of Peyronie's disease. | Q53455553 |
| | Tamoxifen versus placebo in the treatment of Peyronie's disease. | Q55033437 |
| | Surgical treatment of Peyronie's disease by plaque incision and grafting with buccal mucosa | Q57155396 |
| | Updates in inflatable penile prostheses | Q36993666 |
| | Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. | Q37220153 |
| | Peyronie's disease: a critical appraisal of current diagnosis and treatment | Q37225332 |
| | Peyronie's disease intervention trials: methodological challenges and issues | Q37366843 |
| | Use of tissue engineering in treatment of the male genitourinary tract abnormalities | Q37705572 |
| | The management of Peyronie's disease: evidence-based 2010 guidelines | Q37760270 |
| | Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. | Q38269860 |
| | Classification and biological distribution of histamine receptor sub-types | Q39071854 |
| | Penile dermal flap in patients with Peyronie's disease: long-term results. | Q39207893 |
| | Outcome analysis for conservative management of Peyronie's disease | Q39352017 |
| | A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. | Q39383271 |
| | Evaluation of extracorporeal shock wave therapy in Peyronie's disease | Q39401129 |
| | Is colchicine effective in Peyronie's disease? A pilot study | Q39482557 |
| | Basic fibroblast growth factor expression in Peyronie's disease | Q39557510 |
| | IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease | Q39976615 |
| | Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses | Q40618953 |
| | Organ-specific acellular matrix for reconstruction of the urinary tract | Q41730298 |
| | Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model | Q44225755 |
| | Tunica albuginea tissue analysis after electromotive drug administration | Q44398116 |
| | Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma | Q44413643 |
| | L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures | Q44783709 |
| | Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades | Q44810541 |
| | The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study | Q44934972 |
| | Surgical treatment of Peyronie's disease based on penile length and degree of curvature | Q44950919 |
| | Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways | Q45238420 |
| | Intralesional injection therapy for Peyronie's disease. | Q45941055 |
| | Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease. | Q46035142 |
| | Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique | Q46175331 |
| | Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease | Q46447172 |
| | Systemic vascular endothelial dysfunction in Peyronie's disease | Q46475562 |
| | The surgical treatment of Peyronie's disease: replacement of plaque by free autograft of buccal mucosa | Q46556951 |
| | Complications of porcine small intestine submucosa graft for Peyronie's disease | Q46575770 |
| | Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression | Q46755198 |
| | The dorsal lamina of the rectus sheath: a suitable grafting material for the penile tunica albuginea in Peyronie's disease? | Q46841505 |
| | Transdermal iontophoresis with dexamethasone and verapamil for Peyronie's disease | Q46919951 |
| | Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. | Q46936674 |
| | Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials | Q47275110 |
| | Radiation increases fibrogenic cytokine expression by Peyronie's disease fibroblasts | Q47847896 |
| | The combination of vein grafting and two different types of corporeal plication in complex curvature due to Peyronie's disease | Q48366704 |
| | Peyronie's Disease. | Q50882712 |
| | The results of plaque incision and venous grafting (Lue procedure) to correct the penile deformity of Peyronie's disease. | Q51497388 |
| | Peyronie's disease with erectile dysfunction: penile modeling over inflatable penile prostheses. | Q51501216 |
| | Soft prosthesis implant and relaxing albugineal incision with saphenous grafting for surgical therapy of Peyronie's disease: a 5-year experience and long-term follow-up on 145 operated patients. | Q51551023 |
| | Long-term patient satisfaction after surgical correction of penile curvature via tunical plication. | Q53178418 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Peyronie's disease | Q874586 |
| | minimally-invasive procedures | Q1755504 |
| P304 | page(s) | 931-944 | |
| P577 | publication date | 2011-04-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options | |
| P478 | volume | 12 | |